Lehle Karla, Philipp Alois, Zeman Florian, Lunz Dirk, Lubnow Matthias, Wendel Hans-Peter, Göbölös Laszlo, Schmid Christof, Müller Thomas
Department of Cardiothoracic Surgery, University Medical Center Regensburg, Regensburg, Germany.
Center for Clinical Studies, University Medical Center Regensburg, Regensburg, Germany.
PLoS One. 2015 Nov 25;10(11):e0143527. doi: 10.1371/journal.pone.0143527. eCollection 2015.
The aim of the study was to explore the prevalence and risk factors for technical-induced hemolysis in adults supported with veno-venous extracorporeal membrane oxygenation (vvECMO) and to analyze the effect of hemolytic episodes on outcome. This was a retrospective, single-center study that included 318 adult patients (Regensburg ECMO Registry, 2009-2014) with acute respiratory failure treated with different modern miniaturized ECMO systems. Free plasma hemoglobin (fHb) was used as indicator for hemolysis. Throughout a cumulative support duration of 4,142 days on ECMO only 1.7% of the fHb levels were above a critical value of 500 mg/l. A grave rise in fHb indicated pumphead thrombosis (n = 8), while acute oxygenator thrombosis (n = 15) did not affect fHb. Replacement of the pumphead normalized fHb within two days. Neither pump or cannula type nor duration on the first system was associated with hemolysis. Multiple trauma, need for kidney replacement therapy, increased daily red blood cell transfusion requirements, and high blood flow (3.0-4.5 L/min) through small-sized cannulas significantly resulted in augmented blood cell trauma. Survivors were characterized by lower peak levels of fHb [90 (60, 142) mg/l] in comparison to non-survivors [148 (91, 256) mg/l, p≤0.001]. In conclusion, marked hemolysis is not common in vvECMO with modern devices. Clinically obvious hemolysis often is caused by pumphead thrombosis. High flow velocity through small cannulas may also cause technical-induced hemolysis. In patients who developed lung failure due to trauma, fHb was elevated independantly of ECMO. In our cohort, the occurance of hemolysis was associated with increased mortality.
本研究旨在探讨接受静脉-静脉体外膜肺氧合(vvECMO)支持的成人患者技术诱导溶血的患病率及危险因素,并分析溶血发作对预后的影响。这是一项回顾性单中心研究,纳入了318例接受不同现代小型ECMO系统治疗的急性呼吸衰竭成年患者(雷根斯堡ECMO登记处,2009 - 2014年)。游离血浆血红蛋白(fHb)用作溶血指标。在ECMO累计支持时长4142天期间,仅有1.7%的fHb水平高于500mg/l的临界值。fHb严重升高提示泵头血栓形成(n = 8),而急性氧合器血栓形成(n = 15)未影响fHb。更换泵头后,fHb在两天内恢复正常。泵或插管类型以及在首个系统上的使用时长均与溶血无关。多处创伤、需要肾脏替代治疗、每日红细胞输注需求增加以及通过小尺寸插管的高血流量(3.0 - 4.5L/min)均显著导致血细胞损伤增加。与非幸存者[148(91,256)mg/l,p≤0.001]相比,幸存者的fHb峰值水平较低[90(60,142)mg/l]。总之,在使用现代设备的vvECMO中,明显溶血并不常见。临床上明显的溶血通常由泵头血栓形成引起。通过小插管的高流速也可能导致技术诱导溶血。在因创伤导致肺衰竭的患者中,fHb升高与ECMO无关。在我们的队列中,溶血的发生与死亡率增加相关。